CHEK2 and breast carcinoma: A small Finnish study also found a significant risk from the CHEK2 c.1100delC PV which was found in 4 out of 84 patients (5.9%), significantly more frequently than in the controls (OR=4.47, 95% CI=1.51–13.18, p=0.019).7 Finally, a testing study of panel testing from Ambry genetics of 715 MBCs found a headline PV detection rate of 18.1% for 16 breast cancer susceptibility genes and with no prior BRCA1/2 testing (n=480).